RecruitingNCT06928818
Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea
Prospective Observational Study of Trastuzumab Emtansine Immediately After Trastuzumab Deruxtecan in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Korea
Sponsor
Seoul National University Hospital
Enrollment
100 participants
Start Date
Feb 26, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
Prospective observational study of trastuzumab emtansine immediately after trastuzumab deruxtecan in patients with advanced HER2-positive breast cancer in Korea
Eligibility
Min Age: 19 Years
Inclusion Criteria3
- HER2-positive, advanced (unresectable locally advanced or metastatic) breast cancer
- Prior treatment with trastuzumab deruxtecan(T-DXd) in the advanced setting
- Intention to treat with Trastuzumab Emtansine (T-DM1) as first therapy upon T-DXd progression
Exclusion Criteria4
- Any systemic treatment, other than T-DM1, for breast cancer after trastuzumab deruxtecan (As an exception, patients treated with endocrine agents, not in combination with cytotoxics or antibody-drug conjugates, will be permitted in the study)
- Has been previously treated with T-DM1 for advanced breast cancer
- Has been previously treated with 4 or more lines of therapy for advanced breast cancer
- Half (50%) or more patients will be those who were treated with second-line trastuzumab deruxtecan (i.e. patients at the later line will be capped).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06928818
Related Trials
A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients
NCT072810011 location
Cancer Pain Management Using a Web-based Intervention
NCT060853131 location
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
NCT024767861 location
A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer
NCT064716731 location
Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy
NCT061258341 location